Ethics Board Needed to Help FDA With Postmarket Risk-Benefit Assessments: NEJM Report

Drug Industry Daily
A A
An independent ethics advisory board is needed to help the FDA asses the risks and benefits of approved drugs and firm up its decisionmaking on postmarket safety issues, according to a new report.

To View This Article:

Login

Subscribe To Drug Industry Daily